newsfilter
← Latest News
PR Newswire·

CalciMedica Reports First Quarter 2026 Financial Results and Provides Clinical & Corporate Updates

CALC
  • FDA feedback on the Auxora pivotal program for acute pancreatitis (AP) & potential future development in acute kidney injury (AKI) is expected in Q2 2026.
  • Preclinical & IND-enabling studies for CM5480, an oral CRAC channel inhibitor candidate for pulmonary hypertension, are advancing with an IND submission anticipated in 2027.
  • The Phase 2b CARPO trial results for Auxora in AP were published in February 2026, showing dose-dependent reductions in time to solid food tolerance, organ failure, & new-onset severe respiratory failure.
  • Preclinical data published in April 2026 in Human Immunology demonstrated that SOCE blockers selectively modulate inflammatory pathways while preserving anti-inflammatory pathways in regulatory T cells.
  • Following a pause in enrollment for the KOURAGE trial in AKI, safety reviews identified no drug-related toxicity, with FDA feedback on future development expected in Q2 2026.
  • Cash & cash equivalents totaled $8.2 million as of March 31, 2026, sufficient to fund operations through Q4 2026.
  • R&D expenses decreased to $3.5 million in Q1 2026 from $4.2 million in Q1 2025 due to reduced preclinical, clinical, & manufacturing activities.
  • G&A expenses decreased to $2.1 million in Q1 2026 from $2.3 million in Q1 2025 primarily due to lower personnel costs.
  • Other income increased to $10.6 million in Q1 2026 from $1.5 million in Q1 2025, driven by fair value adjustments to promissory notes & common stock warrants.
  • The company reported a net income of $5.0 million ($0.31 per basic share) for Q1 2026, compared to a net loss of $5.0 million in the same period last year.